

# Congress of the United States

Washington, DC 20515

February 13, 2023

The Honorable Xavier Becerra  
Secretary  
Department of Health and Human Services  
200 Independence Ave., SW  
Washington, D.C. 20201

Dear Secretary Becerra:

Pursuant to H. Res. 5, the issues outlined in the Committee on Oversight and Accountability's (f.k.a. the Committee on Oversight and Reform) December 13, 2022, letter to you now fall under the purview of both the Committee and the Select Subcommittee on the Coronavirus Pandemic.<sup>1</sup> As such, we renew the December 13<sup>th</sup> requests to be produced as soon as possible but no later than February 20, 2023. For your ready reference, those requests are as follows:

1. All official calendars from November 1, 2019, through present for the following individuals:
  - a. Dr. Francis Collins;
  - b. Dr. Anthony Fauci;
  - c. Dr. Lawrence Tabak;
  - d. Dr. Hugh Auchincloss;
  - e. Dr. Michael Lauer; and
  - f. Dr. David Christian Hassell
  
2. All official phone records, including landlines and cell phones, from November 1, 2019, through present for the following individuals:
  - a. Dr. Francis Collins;
  - b. Dr. Anthony Fauci;
  - c. Dr. Lawrence Tabak;
  - d. Dr. Hugh Auchincloss;
  - e. Dr. Michael Lauer; and
  - f. Dr. David Christian Hassell
  
3. All documents and communications regarding Scientific Review Group, including the Clinical Research and Field Studies of Infectious Diseases Study Section, review of

---

<sup>1</sup> H. Res. 5 (2023); Letter from Hon. James Comer, Ranking Member, H. Comm. on Oversight & Reform, & Hon. Jim Jordan, Ranking Member, H. Comm. on the Judiciary, to Hon. Xavier Becerra, Sec'y, U.S. Dep't of Health & Human Servs. (Dec. 13, 2022).

R01AI110964, including but not limited to meeting minutes and a final report, memorandum, decision, or summary statement.

4. All documents and communications regarding NIAID National Advisory Allergy and Infectious Disease Council review of R01AI110964-01, including but not limited to meeting minutes and a final report, memorandum, decision, or summary statement.
5. All documents and communications between and among NIH, NIAID, and HHS employees regarding grant R01AI110964, to include all grant years and any subsequent related grants, from January 1, 2014 through present.
6. All documents and communications between and among NIH, NIAID, and/or HHS employees regarding the WIV from January 1, 2014, through present.
7. All documents and communications between and among NIH and/or NIAID employees and employees of the WIV from January 1, 2014, through present.
8. All documents and communications between and among NIH, NIAID, and/or HHS employees and EcoHealth employees, or affiliated individuals, regarding grant R01AI110964, to include all grant years and any subsequent related grants, from January 1, 2014, through present.
9. All documents and communications between and among NIH, NIAID, and/or HHS employees and EcoHealth employees, or affiliated individuals, regarding the letter published in *The Lancet* entitled “Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19.”
10. All documents and communications between and among NIH, NIAID, and/or HHS employees and EcoHealth employees, or affiliated individuals, regarding the paper published in *Nature Medicine* entitled “The Proximal Origin of COVID-19.”
11. All documents and communications between and among NIH and/or NIAID employees and HHS employees regarding R01AI110964 and any related review by the Potential Pandemic Pathogen Care and Oversight Framework (P3CO) review board.
12. All documents and communications regarding the formulation, creation, and publication of the October 17, 2014, U.S. Government Gain-of-Function Deliberative Process and Research Funding Pause on Selected Gain-of-Function Research Involving Influenza, MERS, and SARS Viruses.
13. All documents and communications regarding the formulation, creation, and publication of the December 19, 2017, Framework for Guiding Funding Decisions about Proposed Research Involving Enhanced Potential Pandemic Pathogens.

14. All drafts of “The Proximal Origins of SARS-CoV-2” between January 31, 2020, and March 17, 2020, including all drafts with track changes and comments visible.
15. All documents and communications regarding, referring, or relating to the February 1, 2020, teleconference or any subsequent telephone call, conference, or meeting regarding the origins of COVID-19.
16. All documents and communications regarding the drafting, publication, and critical reception of “The Proximal Origins of SARS-CoV-2” published in *Nature Magazine*.

In addition to the above requests, please also produce any and all documents and information and include the Select Subcommittee on all activities produced in response to or resulting from the Committee on Energy and Commerce’s February 2, 2023 request to Dr. Lawrence Tabak.

Further, we also renew our request for testimony. Accordingly, Select Subcommittee staff will contact you to schedule transcribed interviews with the following individuals, reserving the right to conduct follow-up interviews or request testimony from other witnesses pertinent to our investigation.

### **HHS**

1. Ms. Melanie Egorin, Assistant Secretary for Legislation; and
2. Mr. Samuel Bagenstos, General Counsel

### **NIH**

3. Dr. Lawrence Tabak, Acting Director;
4. Ms. Adrienne Hallett, Associate Director, Legislative Policy and Analysis;
5. Dr. Michael Lauer, Deputy Director for Extramural Research; and
6. Ms. Michelle Bulls, Director, Office of Policy for Extramural Research Administration.

### **NIAID**

7. Dr. Hugh Auchincloss, Acting Director;
8. Ms. Courtney Billet, Director, Office of Congressional and Government Relations;
9. Mr. Greg Folkers, Chief of Staff;
10. Dr. Ping Chen, Project Officer;
11. Dr. Erik Stemmy, Program Officer;
12. Dr. Cliff Lane, Deputy Director for Clinical Research and Special Projects;
13. Dr. Emily Erbelding, Director, Division of Microbiology and Infectious Diseases;
14. Ms. Emily Linde, Director, Grants Management Program;
15. Dr. Matthew Fenton, Director, Division of Extramural Activities;
16. Dr. Jill Harper, Deputy Director for Science Management; and
17. Dr. David Morens, Senior Scientific Advisor.

**P3CO**

18. Dr. David Christian Hassell, Senior Science Advisor, Office of the Assistant Secretary for Preparedness and Response
19. Dr. Ruben Donis, Chief Science Officer, Influenza Division, Biomedical Advanced Research and Development Authority
20. Dr. Jeffrey Taubenberger, Senior Investigator, Viral Pathogenesis and Evolution Section, NIH
21. Dr. Segaran Pillai, Director, Office of Laboratory Safety, Food and Drug Administration
22. Dr. Samuel Edwin, Director, Division of Select Agents and Toxins, Center for Preparedness and Response, Centers for Disease Control and Prevention
23. Dr. Ken Santora, Director, Division of Extramural Activities, National Institute on Aging, NIH
24. Dr. Daniel Jernigan, Acting Deputy Director, Public Health Science and Surveillance, Centers for Disease Control and Prevention
25. Dr. Carrie Wolinetz, Acting Chief of Staff and Associate Director for Science Policy, NIH
26. Mr. Garret Grigsby, Former Director, Office of Global Affairs, HHS
27. Ms. Alisa Hudgens, Acting Deputy Director, Office of National Security, HHS
28. Ms. Susan Sherman, Senior Attorney, HHS; and
29. Mr. Bill Hall, Deputy Assistant Secretary for Public Affairs, Public Health, HHS.


The Select Subcommittee on the Coronavirus Pandemic is authorized to investigate “the origins of the Coronavirus pandemic, including but not limited to the Federal Government’s funding of gain-of function research” and “executive branch policies, deliberations, decisions, activities, and internal and external communications related to the coronavirus pandemic” under H. Res. 5. Further, the Committee on Oversight and Accountability is authorized to investigate “any matter” at “any time” pursuant to House Rule X. To schedule the interviews or ask any follow up or related questions please contact Committee staff at (202) 225-5074.

Thank you for your attention to this very important matter.

Sincerely,



Brad R. Wenstrup, D.P.M.  
Chairman  
Select Subcommittee on the  
Coronavirus Pandemic



James Comer  
Chairman  
Committee on Oversight and  
Accountability




Nicole Malliotakis  
Member of Congress



Mariannette Miller-Meeks, M.D.  
Member of Congress



John Joyce, M.D.  
Member of Congress



Ronny Jackson, M.D.  
Member of Congress



Michael Cloud  
Member of Congress



Debbie Lesko  
Member of Congress



Marjorie Taylor Greene  
Member of Congress



Rich McCormick, M.D., M.B.A.  
Member of Congress

cc: The Honorable Jamie Raskin, Ranking Member  
Committee on Oversight and Accountability

The Honorable Raul Ruiz, M.D., Ranking Member  
Select Subcommittee on the Coronavirus Pandemic

The Honorable Cathy McMorris Rodgers, Chair  
Committee on Energy and Commerce

The Honorable Frank Pallone, Ranking Member  
Committee on Energy and Commerce

The Honorable Morgan Griffith, Chairman  
Committee on Energy and Commerce  
Subcommittee on Oversight and Investigations

The Honorable Xavier Becerra  
February 13, 2023  
Page 6

The Honorable Kathy Castor, Ranking Member  
Committee on Energy and Commerce  
Subcommittee on Oversight and Investigations